NEW YORK, Nov 18, 2009 /PRNewswire via COMTEX/ ----Reportlinker.com announces that a new market research report is available in its catalogue.

Anticoagulants - A Global Market Review

http://www.reportlinker.com/p0164225/Anticoagulants---A-Global-Market-Review.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

The world anticoagulants market is driven by patent expiries, development of novel therapeutics, and rapidly aging population. With just two therapy classes - vitamin K antagonist and heparin injectables, dominating the market, there exist enormous opportunities and interest in developing advanced, patient friendly anticoagulants. Favorable demographic patterns, like the rapidly aging world population is expected to drive demand patterns, given the tendency of aging individuals to develop various venous and arterial complications.

The unmet medical needs of available anticoagulants offer ample scope for development in the world anticoagulants market. Continuous research and development is expected to result in novel therapies with superior therapeutic efficiency, and minimum side effects. These advanced therapeutics offer promising market prospects. Identification of new indications for existing, and emerging therapies is expected to help open up brighter prospects for further growth. Factor Xa inhibitors (oral and injectable) and direct thrombin inhibitors (oral and injectable) are among the new class of thrombin antagonists that are being evaluated for both existing as well as newer indications.

These and other market data and trends are presented in "Anticoagulants: A Global Market Review" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

ANTICOAGULANTS BMR-1025

CONTENTS

1. METHODOLOGY 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Quantitative Techniques & Reporting Level 3

2. GLOBAL MARKET OVERVIEW AND OUTLOOK 4

3. MARKET SCENARIO 4

A Snapshot of Available Therapies 5

An Insight into Currently Available Antithrombotic Drugs 5

Weaknesses of Available Therapies 6

Forces Driving the Market 6

Oral Anticoagulants Market 6

Injectable Anticoagulants Market 7

Heparin Market 7

LMWH Market 7

4. MARKET DYNAMICS 8

Drug Advancements Drive Anticoagulant Market 8

Niche Markets - The New Target for Drug Makers 8

An Opportunity to Grow Further 8

Geriatric Patients - At High Risk of Blood Clots 9

Improved Anticoagulant Agents for Children Group 9

Growing Demand for Self-Testing 9

LMWHs Eases Outpatient Management 9

Concern Over Underutilization of Warfarin 10

Anticoagulants to Lose UA/AMI Markets to Antiplatelets 10

Influx of New Drugs Invigorates the Market 10

Novel Heparins Enhances Market Potential 11

Anticoagulant Therapy During Pregnancy Improves Outcomes 11

New Therapies: Need of the Hour 11

Anticoagulant Therapy in IPF: Reduces Mortality Risk 11

Failure of Exanta 12

5. PRODUCT FACTS 12

Anticoagulants 12

Indications for Anticoagulant Use 12

List of Approved Anticoagulants for Pulmonary Embolism 13

List of Approved Anticoagulants for Orthopedic Surgery 13

List of Approved Anticoagulants for General Surgery 13

List of Approved Anticoagulants for Atrial Fibrillation 14

List of Approved Anticoagulants for Unstable Angina 14

List of Approved Anticoagulants for Non-ST Segment Elevation

Myocardial Infraction 14

List of Approved Anticoagulants for Angioplasty Procedures 15

List of Approved Anticoagulants for HIT Type II 15

6. DRUG DEVELOPMENT PIPELINE 15

Select Anticoagulants Under Pipeline 15

Idraparinux - Sanofi-Aventis 16

0673 - Sanofi-Aventis 16

BIBR1048MS - Boehringer Ingelheim 17

7. CORPORATE DEVELOPMENTS 17

PAION Acquires CeNes Pharmaceuticals 17

PAION Announces Acquisition of Global Rights to Trigen's

flovagatran 17

Biological E Collaborates with Choncept and Heparinex 17

Bayer's Market Expansion 18

B. Braun Recalls Heparin Sodium Based Injection Solutions 18

Baxter Recalls Heparin Sodium Vials 18

Boehringer Receives EU Approval for Pradaxa 18

Sanofi-Aventis Receives Approval for Clexane(R) in Japan 19

ParagonDx Receives US FDA Approval for its Rapid Genotyping Assay 19

Lannett Obtains US FDA Approval for Dipyridamole Tablets 19

Celgene Acquires Pharmion 19

BMS Collaborates with Pfizer 20

Medicines Company Reacquires European Rights for Angiox 20

HemoSense and LabCorp Sign Agreement for Supply of INRatio System 21

Sanofi-Aventis Acquires Rights for Panaldine from Daiichi 21

Alchemia Inks Marketing Alliance with Dr Reddy's for Heparin 21

Inverness Announces Acquisition of HemoSense 22

ev3, FoxHollow Complete Merger 22

Osmetech Signs Licensing Agreement with Marshfield Clinic 22

Mitsubishi and Tanabe Agree to Merge 23

Artisan and A-Bio Form Alliance 23

Kimball Introduces New Pharmacogenetic Test 23

Roche Launches an Improved Point-of- Care Anticoagulation

Monitoring System 24

Danish Agency Grants Approval for Anticoagulant Clinical Trials 24

EMEA Approves ARIXTRA(R) of GlaxoSmithKline 24

FDA Approves ANDAs of PLIVA 24

FDA Approves ARIXTRA Injection of GSK 24

Japanese Ministry Approves Arixtra of GSK 25

Eisai Obtains FDA Approval for Fragmin 25

Sanofi-Aventis' Lovenox(R) Obtains FDA Approval for Acute

Cardiac Care 25

8. MAJOR PLAYERS 26

AstraZeneca PLC (UK) 26

Bristol-Myers Squibb Company (USA) 26

Celgene Corporation (USA) 26

GlaxoSmithKline plc (UK) 26

Mitsubishi Tanabe Pharma Corporation (Japan) 27

Pfizer Inc. (USA) 27

Sanofi-Aventis (France) 27

9. MARKET ANALYTICS 28

10. THE UNITED STATES 34

Atrial Fibrillation - A Key Risk Factor 34

Regulatory Route to the US Market 34

Phase I Clinical Trials 34

Phase II Clinical Trials 34

Phase III Clinical Trials 34

Price Controls 35

US Anticoagulants Market 35

US Heparin Market 35

Hinging on Market Opportunities 36

Generics - Threatening Branded Anticoagulants 36

List of Patent Protected Anticoagulants in the US 37

Ignorance - A Major Hindrance 37

Future Challenges and Growth Drivers 37

US Emerging Anticoagulant Market 38

US Emerging Anticoagulants Market: Products in the Pipeline 38

11. JAPAN 40

Anticoagulants Market in Japan 40

Rising Incidence of Pulmonary Thromboembolism 40

12. EUROPE 42

a. France 45

b. Germany 46

c. Italy 47

d. The United Kingdom 48

e. Spain 49

f. Rest of Europe 50

13. REST OF WORLD 51

Table 1: Global Anticoagulants Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 2: Percentage Breakdown of Global Anticoagulants Market

by Region for the Years 2008 & 2012

Table 3: Global Oral Anticoagulants Market by Region for the

Period 2007-2015 (Sales in US$ Million)

Table 4: Percentage Breakdown of Global Oral Anticoagulants

Market by Region for the Years 2008 & 2012

Table 5: Global Injectable Anticoagulants Market by Region for

the Period 2007-2015 (Sales in US$ Million)

Table 6: Percentage Breakdown of Global Injectable

Anticoagulants Market by Region for the Years 2008 & 2012

Table 7: Global Injectable Anticoagulants Market by Segment

for the Period 2007-2015 (Sales in US$ Million)

Table 8: Percentage Breakdown of Global Injectable

Anticoagulants Market by Segment for the Years 2008 & 2012

Table 9: Global Unfractionated Heparin Market by Region for

the Period 2007-2015 (Sales in US$ Million)

Table 10: Percentage Breakdown of Global Unfractionated

Heparin Market by Region for the Years 2008 & 2012

Table 11: Global Low Molecular Weight Heparin Market by Region

for the Period 2007-2015 (Sales in US$ Million)

Table 12: Percentage Breakdown of Global Low Molecular Weight

Heparin Market by Region for the Years 2008 & 2012

Table 13: Anticoagulants Market by Segment in the US:

2007-2015 (Sales in US$ Million)

Table 14: Percentage Breakdown of Anticoagulants Market by

Segment in the US for the Years 2008 & 2012

Table 15: Anticoagulants Market by Segment in Japan: 2007-2015

(Sales in US$ Million)

Table 16: Percentage Breakdown of Anticoagulants Market by

Segment in Japan for the Years 2008 & 2012

Table 17: Anticoagulants Market by Region in Europe: 2007-2015

(Sales in US$ Million)

Table 18: Percentage Breakdown of Anticoagulants Market by

Region in Europe for the Years 2008 & 2012

Table 19: Anticoagulants Market by Segment in Europe:

2007-2015 (Sales in US$ Million)

Table 20: Percentage Breakdown of Anticoagulants Market by

Segment in Europe for the Years 2008 & 2012

Table 21: Anticoagulants Market by Segment in France:

2007-2015 (Sales in US$ Million)

Table 22: Percentage Breakdown of Anticoagulants Market by

Segment in France for the Years 2008 & 2012

Table 23: Anticoagulants Market by Segment in Germany:

2007-2015 (Sales in US$ Million)

Table 24: Percentage Breakdown of Anticoagulants Market by

Segment in Germany for the Years 2008 & 2012

Table 25: Anticoagulants Market by Segment in Italy: 2007-2015

(Sales in US$ Million)

Table 26: Percentage Breakdown of Anticoagulants Market by

Segment in Italy for the Years 2008 & 2012

Table 27: Anticoagulants Market by Segment in the UK:

2007-2015 (Sales in US$ Million)

Table 28: Percentage Breakdown of Anticoagulants Market by

Segment in the UK for the Years 2008 & 2012

Table 29: Anticoagulants Market by Segment in Spain: 2007-2015

(Sales in US$ Million)

Table 30: Percentage Breakdown of Anticoagulants Market by

Segment in Spain for the Years 2008 & 2012

Table 31: Anticoagulants Market by Segment in the Rest of

Europe: 2007-2015 (Sales in US$ Million)

Table 32: Percentage Breakdown of Anticoagulants Market by

Segment in the Rest of Europe for the Years 2008 & 2012

Table 33: Anticoagulants Market by Segment in Rest of World:

2007-2015 (Sales in US$ Million)

Table 34: Percentage Breakdown of Anticoagulants Market by

Segment in Rest of World for the Years 2008 & 2012

COMPANIES PROFILED

To order this report:

Anticoagulants - A Global Market Review

http://www.reportlinker.com/p0164225/Anticoagulants---A-Global-Market-Review.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire

More market research reports here!

Contact: Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

http://www.reportlinker.com
   

Copyright (C) 2009 PR Newswire. All rights reserved